CCCC
Income statement / Annual
Last year (2023), C4 Therapeutics, Inc.'s total revenue was $20.76 M,
a decrease of 33.25% from the previous year.
In 2023, C4 Therapeutics, Inc.'s net income was -$132.49 M.
See C4 Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$20.76 M |
$31.10 M |
$45.79 M |
$33.20 M |
$21.38 M |
$19.36 M |
| Cost of Revenue |
$117.71 M
|
$7.57 M
|
$2.91 M
|
$77.47 M
|
$47.66 M
|
$28.59 M
|
| Gross Profit |
-$96.95 M
|
$23.52 M
|
$42.88 M
|
-$44.27 M
|
-$26.28 M
|
-$9.23 M
|
| Gross Profit Ratio |
-4.67
|
0.76
|
0.94
|
-1.33
|
-1.23
|
-0.48
|
| Research and Development Expenses |
$117.71 M
|
$117.84 M
|
$94.67 M
|
$78.44 M
|
$48.06 M
|
$28.59 M
|
| General & Administrative Expenses |
$42.08 M
|
$42.79 M
|
$33.25 M
|
$15.20 M
|
$8.77 M
|
$7.16 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$42.08 M
|
$42.79 M
|
$33.25 M
|
$15.20 M
|
$8.77 M
|
$7.16 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$325,000.00
|
-$7,000.00
|
| Operating Expenses |
$159.79 M
|
$160.63 M
|
$127.92 M
|
$93.64 M
|
$56.83 M
|
$35.75 M
|
| Cost And Expenses |
$159.79 M
|
$160.63 M
|
$127.92 M
|
$93.64 M
|
$56.83 M
|
$35.75 M
|
| Interest Income |
$9.81 M
|
$3.58 M
|
$387,000.00
|
$393,000.00
|
$1.83 M
|
$685,000.00
|
| Interest Expense |
$1.37 M
|
$2.22 M
|
$2.15 M
|
$1.23 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$7.74 M
|
$7.57 M
|
$2.91 M
|
$2.84 M
|
$2.74 M
|
$3.57 M
|
| EBITDA |
-$122.10 M |
-$124.28 M |
-$78.84 M |
-$62.89 M |
-$30.56 M |
-$15.12 M |
| EBITDA Ratio |
-5.88
|
-4.05
|
-1.75
|
-1.76
|
-1.58
|
-0.78
|
| Operating Income Ratio |
-6.7
|
-4.17
|
-1.79
|
-1.82
|
-1.66
|
-0.85
|
| Total Other Income/Expenses Net |
$7.82 M
|
$1.36 M
|
-$1.76 M
|
-$6.51 M
|
$2.16 M
|
$678,000.00
|
| Income Before Tax |
-$131.21 M
|
-$128.18 M
|
-$83.89 M
|
-$66.96 M
|
-$33.30 M
|
-$15.71 M
|
| Income Before Tax Ratio |
-6.32
|
-4.12
|
-1.83
|
-2.02
|
-1.56
|
-0.81
|
| Income Tax Expense |
$1.28 M
|
-$1.68 M
|
$2.15 M
|
-$626,000.00
|
$804,000.00
|
$678,000.00
|
| Net Income |
-$132.49 M
|
-$126.50 M
|
-$86.04 M
|
-$66.34 M
|
-$34.10 M
|
-$15.71 M
|
| Net Income Ratio |
-6.38
|
-4.07
|
-1.88
|
-2
|
-1.59
|
-0.81
|
| EPS |
-2.67 |
-2.59 |
-1.87 |
-1.54 |
-0.79 |
-1.06 |
| EPS Diluted |
-2.67 |
-2.59 |
-1.87 |
-1.54 |
-0.79 |
-1.06 |
| Weighted Average Shares Out |
$49.64 M
|
$48.86 M
|
$46.04 M
|
$43.06 M
|
$42.99 M
|
$14.79 M
|
| Weighted Average Shares Out Diluted |
$49.64 M
|
$48.86 M
|
$46.04 M
|
$43.06 M
|
$42.99 M
|
$42.09 M
|
| Link |
|
|
|
|
|
|
